Clinical Trial Update: A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma [Phase 1]

View source ↗

Summary

Genentech completed a Phase 1 study of the investigational agent DEDN6526A in patients with metastatic or unresectable malignant melanoma. The update describes …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• DEDN6526A

Snippet

Sponsor: Genentech, Inc. | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED